Understanding insomnia: Diagnosis and management of a common sleep disorder—CME Information

Continue to Article

CME Test
FREE 1.5 CME Credits

Release Date: October 1, 2007

Expiration Date: September 30, 2008

Learning Objectives

At the conclusion of this activity, participants should be better able to:

• Explain the roles of homeostatic sleep control and the circadian pacemaker in controlling the sleep-wake cycle

• Identify risk factors for insomnia and determine the appropriate screening for and diagnosis of insomnia

• Describe the correlation between insomnia and psychiatric disorders, especially depression

• Evaluate current and emerging treatment therapies for acute and chronic insomnia on the basis of efficacy and safety

Accreditation Statement

The Chatham Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Chatham Institute designates this medical activity for a maximum of 1.5 AMA PRA Category 1 Credits^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

This newsletter has been designed to meet the educational needs of primary care physicians who are interested in learning about the diagnosis and management of insomnia.

Disclosures

It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty, planners, and managers who affect the content of medical education activities sponsored by The Chatham Institute are required to disclose any real or apparent conflict of interest related to the activity. Faculty, planners, and managers not complying with the disclosure policy will not be permitted to participate in this activity. Disclosure information is provided below.

Program faculty and planners have disclosed the financial relationships with commercial interests cited below. All program content has been peer reviewed for balance and any potential bias. The conflict of interest resolution process aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

• Joseph A. Lieberman III, MD, MPH
  Advisory Board: AstraZeneca Pharmaceuticals LP, Pfizer Inc, sanofi-aventis U.S. LLC, Takeda Pharmaceuticals North America, Inc.
  Speaker Bureau: Takeda Pharmaceuticals North America, Inc.

• David N. Neubauer, MD
  Advisory Board: Neurocrine Biosciences, Inc., Pfizer Inc, sanofi aventis U.S. LLC, Takeda Pharmaceuticals North America, Inc.
  Speaker Bureau: sanofi aventis U.S. LLC, Takeda Pharmaceuticals North America, Inc.

• Daniel Duch, PhD
  Scientific Director, The Chatham Institute No real or apparent conflicts to report

Acknowledgement

This CME activity was supported by an educational grant from sanofi aventis U.S. LLC.

This material has been submitted by The Chatham Institute. It has been edited and peer reviewed by The Journal of Family Practice.

Continue to Article